Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.31 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756500 | 0.86 | CA14 (0.43) | CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL4519025 | 0.86 | CA14 (0.46) | CA14HDAC1HDAC2HDAC6KCNQ4 | |
| SCHEMBL6140672 | 0.86 | CA14 (0.42) | CA14HDAC1HDAC2HDAC6KCNQ4 | |
| SCHEMBL5460363 | 0.85 | CA14 (0.53) | CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL31324971 | 0.83 | CA14 (0.51) | CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL1274075 | 0.83 | CA14 (0.55) | CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL30942676 | 0.83 | CA14 (0.40) | CA14HDAC1HDAC2HDAC6KCNQ4 | |
| SCHEMBL27346056 | 0.83 | CA14 (0.47) | CA14HDAC1HDAC2HDAC6KCNQ4 | |
| SCHEMBL1207293 | 0.83 | CA14 (0.39) | CA14HDAC1HDAC2HDAC6KCNQ4 | |
| SCHEMBL1143116 | 0.82 | SSTR4 (0.41) | CA14HDAC1HDAC2HDAC6KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MRPL21, F12, MRPS34 | CA14 3703/4885HDAC1 335/4885HDAC2 1224/4885 |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IKZF3, INTS9, CYP2C9 | CA14 4258/4885HDAC1 637/4885HDAC2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.